Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spartalizumab + Ieramilimab in Advanced Malignancies
NCT03365791Phase 2Completed
- Sponsor
- Novartis
- Start
- Jan 2018
- Primary completion
- Feb 2019
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of spartalizumab, ieramilimab in small cell lung cancer (SCLC), gastric adenocarcinoma, esophageal adenocarcinoma (EAC), castration-resistant prostate cancer (CRPC), soft tissue sarcoma (STS), sponsored by Novartis. Started Jan 2018; status: completed.
02
Drugs
spartalizumabieramilimab
03
Conditions
small cell lung cancer (SCLC)gastric adenocarcinomaesophageal adenocarcinoma (EAC)castration-resistant prostate cancer (CRPC)soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT03365791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03365791.